Article in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 4 institutions in 3 countries.
Bon Ham YipLeukemia and Stem Cell Biology Group, Department of Haematological Medicine, Division of Cancer Studies, King's College London, UK.
Chiou Tsun TsaiLeukemia and Stem Cell Biology Group, Department of Haematological Medicine, Division of Cancer Studies, King's College London, UK.
Jayant K RaneLeukemia and Stem Cell Biology Group, Department of Haematological Medicine, Division of Cancer Studies, King's College London, UK.
Winston VetharoyLeukemia and Stem Cell Biology Group, Department of Haematological Medicine, Division of Cancer Studies, King's College London, UK.
Eduardo AnguitaHaematology Department, Hospital Clínico San Carlos, Madrid, Spain.
Shuo DongSbarro Institute for Cancer Research, College of Science and Technology, Temple University, Philadelphia, PA, USA.
Michael A CaligiuriThe Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, USA.
Chi Wai Eric SoLeukemia and Stem Cell Biology Group, Department of Haematological Medicine, Division of Cancer Studies, King's College London, UK eric.so@kcl.ac.uk.
King's College London · GBHospital Clínico San Carlos · ESTemple University · USThe Ohio State University · US
Funding
SPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 2009 to 2013
$11.2M
Functional Characterization of MLL Gene FusionsR01CA089341 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A · 2002 to 2013
$2.8M
Cancer Research UK 16753NCI NIH HHS P50 CA140158NCI NIH HHS R01 CA089341
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Amplification of mixed lineage leukemia gene perturbs hematopoiesis and cooperates with partial tandem duplication to induce acute myeloid leukemia. · full record | OpenQuestion